Syros halts enrollment in phase II AML study – BioWorld

… retinoid alpha receptor agonist (RARα) gene overexpression. Analysts seemed unconcerned about the repercussions for Syros’ phase III study in …

Continue

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 82% regionally and is currently trending positive.

100%

Media Trust Score100%

Read All

In

Fashion & Beauty